The AVXL stock forecast points to an extended consolidation phase between $8.20 and $9.80, as traders await clinical milestones. A decisive move above $10 could attract risk-on capital into the biotech sector. The considerable ownership by individual investors in Anavex Life Sciences indicates that they collectively have a greater say in management and business strategy Shares of Anavex Life Sciences AVXL , a clinical-stage biotech making medicines to treat central nervous system (CNS) diseases, have skyrocketed 94.7% in the past three months due to recent pipeline successes. AVXL stock forecast for Q3 incorporates both technical and fundamental factors; positive interim trial data could extend stock price toward the upper Bollinger band near $
